Monthly Archives: November 2018

AstraZeneca Reports Full Results from DECLARE-TIMI 58 Cardiovascular Outcomes Trial for FARXIGA (dapagliflozin)

Posted on November 13, 2018 by admin

November 12, 2018;  Reproduced from StreetInsider AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA (dapagliflozin). The data were presented as a late-breaking abstract (#19485) at the American Heart Association (AHA) Scientific Sessions … Continue reading →

Posted in M Loghman-Adham, MD | Leave a comment

Lokelma approved in the US for the treatment of adults with hyperkalemia

Posted on November 12, 2018 by admin

On May 18, 2018 AstraZeneca announced the FDA approval of their new drug Lokelma, for the treatment of hyperkalemia.  The full new release is reproduced below: The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for … Continue reading →

Posted in M Loghman-Adham, MD | Leave a comment